Phase 3 Readout~month

Phase 3 Topline: An Open-label, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of 0.05 mg/kg/Day

Indication
Short Bowel Syndrome

Other upcoming events for TAK

Phase 2 StartPhase 2 Start: An Open-Label, Single-Arm, Phase 2a Trial to Evaluate the Safety, Tolerability, PK, and Mechanism of
Phase 2 StartPhase 2 Start: A Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase 2 Trial to Evaluate the Safety an
Phase 3 ReadoutPhase 3 Topline: An Open-label, Multicenter Clinical Study on The Long-term Safety and Efficacy of Multiple Treatment
Phase 3 ReadoutPhase 3 Topline: An Open-Label, Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intravenous (
Phase 3 ReadoutPhase 3 Topline: A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Effic

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: An Open-label, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of 0.05 mg/kg/Day — TAK Phase 3 Readout | BioSniper